Tag
Identification of a pathogenic E. coli strain overexpressing HtpG that promotes fibrosis in chronic pancreatitis via macrophage-mediated pathways highlights new microbiota-targeted treatment avenues.
The Global-MASLD study identifies key predictors of advanced fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease, highlighting the prognostic value of noninvasive fibrosis markers across diverse populations.
Pancreatic fibrosis activates Schwann cells via nuclear mechanosensing, promoting a protumorigenic environment that enhances pancreatic cancer progression, offering novel microenvironment-targeted therapeutic insights.
AI-assisted digital pathology improves inter-pathologist agreement on fibrosis staging in metabolic dysfunction-associated steatohepatitis (MASH), enhancing clinical trial accuracy and efficiency.
A phase IIb trial of the FFAR1/FFAR4 agonist icosabutate in MASH shows encouraging fibrosis improvement and biomarker responses despite not meeting the primary endpoint, supporting further development.
The phase IIb ICONA trial evaluated icosabutate, a dual FFAR1/FFAR4 agonist, in patients with MASH, showing fibrosis improvement without meeting the primary endpoint, and supporting further development particularly in advanced fibrosis and
The MIRNA study evaluated ervogastat, alone and with clesacostat, in patients with biopsy-confirmed MASH and F2-F3 fibrosis, showing combination therapy achieved significant efficacy in resolving MASH without fibrosis worsening and a manage
Dapagliflozin significantly improves metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis outcomes without increasing adverse events, according to a rigorous 48-week randomized trial.
